Zobrazeno 1 - 10
of 204
pro vyhledávání: '"Onno W. Akkerman"'
Autor:
Paula Niewold, Douwe J. Dijkstra, Yi Cai, Delia Goletti, Fabrizio Palmieri, Krista E. van Meijgaarden, Frank A. W. Verreck, Onno W. Akkerman, Regina W. Hofland, Eveline M. Delemarre, Stefan Nierkens, Marije K. Verheul, Andrew J. Pollard, Jaap T. van Dissel, Tom H. M. Ottenhoff, Leendert A. Trouw, Simone A. Joosten
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Tuberculosis (TB) is a prevalent disease causing an estimated 1.6 million deaths and 10.6 million new cases annually. Discriminating TB disease from differential diagnoses can be complex, particularly in the field. Increased levels of comple
Externí odkaz:
https://doaj.org/article/571b4883ecfe424fa808ac326e39113b
Autor:
Anne M. Akkerman-Nijland, Bart L. Rottier, Joanne Holstein, Rik L.J. Winter, Daniel J. Touw, Onno W. Akkerman, Gerard H. Koppelman
Publikováno v:
ERJ Open Research, Vol 9, Iss 3 (2023)
Externí odkaz:
https://doaj.org/article/b15a6c801768479ba6a3fdfb4dd2d323
Autor:
Elisa Vanino, Bianca Granozzi, Onno W. Akkerman, Marcela Munoz-Torrico, Fabrizio Palmieri, Barbara Seaworth, Simon Tiberi, Marina Tadolini
Publikováno v:
International Journal of Infectious Diseases, Vol 130, Iss , Pp S12-S15 (2023)
In December 2022 World Health Organization released a new treatment for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) guideline. The main novelty of this update is two new recommendations (i) a 6-month treatment regimen composed o
Externí odkaz:
https://doaj.org/article/08c76aff61794afa9b172b861ebc87f4
Autor:
Lina Keutzer, Laurynas Mockeliunas, Marieke G. G. Sturkenboom, Mathieu S. Bolhuis, Onno W. Akkerman, Ulrika S. H. Simonsson
Publikováno v:
Pharmaceuticals, Vol 16, Iss 11, p 1575 (2023)
Long-term usage of linezolid can result in adverse events such as peripheral neuropathy, anemia and thrombocytopenia. Therapeutic drug monitoring data from 75 drug-resistant tuberculosis patients treated with linezolid were analyzed using a time-to-e
Externí odkaz:
https://doaj.org/article/141df131ff23475eb08c004706589575
Autor:
Johanna Kuhlin, Marieke G.G. Sturkenboom, Samiksha Ghimire, Ioana Margineanu, Simone H.J. van den Elsen, Noviana Simbar, Onno W. Akkerman, Erwin M. Jongedijk, Remco A. Koster, Judith Bruchfeld, Daan J. Touw, Jan-Willem C. Alffenaar
Publikováno v:
Journal of Mass Spectrometry and Advances in the Clinical Lab, Vol 25, Iss , Pp 72- (2022)
Externí odkaz:
https://doaj.org/article/894cb48fe5ff46b78425fa46a9f6371b
Autor:
Juan Espinosa-Pereiro, Samiksha Ghimire, Marieke G. G. Sturkenboom, Jan-Willem C. Alffenaar, Margarida Tavares, Sarita Aguirre, Arturo Battaglia, Gladys Molinas, Teresa Tórtola, Onno W. Akkerman, Adrian Sanchez-Montalva, Cecile Magis-Escurra
Publikováno v:
Pharmaceutics, Vol 15, Iss 1, p 9 (2022)
Previous clinical trials for drug-susceptible tuberculosis (DS-TB) have shown that first-line treatment with doses of rifampicin up to 40 mg/kg are safe and increase the early treatment response for young adults with pulmonary tuberculosis. This may
Externí odkaz:
https://doaj.org/article/d0194403c7eb40c1a85ede0bce7d7239
Autor:
Eveline M. Delemarre, Laura van Hoorn, Aik W. J. Bossink, Julia Drylewicz, Simone A. Joosten, Tom H. M. Ottenhoff, Onno W. Akkerman, Delia Goletti, Elisa Petruccioli, Assunta Navarra, Brigitte T. A. van den Broek, Sanne P. A. Paardekooper, Ineke van Haeften, Leo Koenderman, Jan-Willem J. Lammers, Steven F. T. Thijsen, Regina W. Hofland, Stefan Nierkens
Publikováno v:
Frontiers in Immunology, Vol 12 (2021)
IntroductionThere is an urgent medical need to differentiate active tuberculosis (ATB) from latent tuberculosis infection (LTBI) and prevent undertreatment and overtreatment. The aim of this study was to identify biomarker profiles that may support t
Externí odkaz:
https://doaj.org/article/32e9ffc238fc4966a4cd5c1d10890db9
Autor:
Ivan S. Pradipta, Natasha van’t Boveneind-Vrubleuskaya, Onno W. Akkerman, Jan-Willem C. Alffenaar, Eelko Hak
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 8, Iss 1, Pp 1-12 (2019)
Abstract Background Since in low incidence TB countries population migration and complex treatment of drug-resistant tuberculosis (DR-TB) patients are major issues, we aimed to analyse patient risk factors associated with the incidence of poor outcom
Externí odkaz:
https://doaj.org/article/d0e08e6446cb43b38397f3a6b9301954
Autor:
Anne M. Akkerman-Nijland, Bart L. Rottier, Joanne Holstein, Rik L.J. Winter, Daniel J. Touw, Onno W. Akkerman, Gerard H. Koppelman
Publikováno v:
ERJ Open Research. :00055-2023
This case series suggests that successful eradication therapy of BCC in cystic fibrosis can be done with a combination of inhaled and oral medication, which in many cases may eliminate the need for intensive treatment with intravenous antibiotics htt
Autor:
Laurynas Mockeliunas, Lina Keutzer, Marieke G. G. Sturkenboom, Mathieu S. Bolhuis, Lotte M. G. Hulskotte, Onno W. Akkerman, Ulrika S. H. Simonsson
Publikováno v:
Pharmaceutics, Vol 14, Iss 4, p 753 (2022)
Linezolid is an efficacious medication for the treatment of drug-resistant tuberculosis but has been associated with serious safety issues that can result in treatment interruption. The objectives of this study were thus to build a population pharmac
Externí odkaz:
https://doaj.org/article/610cde62416941eb9c0f796f9ffdb1e0